115 related articles for article (PubMed ID: 32674319)
1. Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hürthle Cell Carcinomas of the Thyroid.
Pecce V; Verrienti A; Abballe L; Carletti R; Grani G; Falcone R; Ramundo V; Durante C; Di Gioia C; Russo D; Filetti S; Sponziello M
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32674319
[TBL] [Abstract][Full Text] [Related]
2. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
[TBL] [Abstract][Full Text] [Related]
3. SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
Tsang JY; Lai ST; Ni YB; Shao Y; Poon IK; Kwan JS; Chow C; Shea KH; Tse GM
Breast Cancer Res Treat; 2021 Jun; 187(2):339-347. PubMed ID: 33844099
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers.
Chen R; Zhao WQ; Fang C; Yang X; Ji M
J Cancer; 2020; 11(11):3349-3356. PubMed ID: 32231741
[TBL] [Abstract][Full Text] [Related]
5. SETD2 mutations in primary central nervous system tumors.
Viaene AN; Santi M; Rosenbaum J; Li MM; Surrey LF; Nasrallah MP
Acta Neuropathol Commun; 2018 Nov; 6(1):123. PubMed ID: 30419952
[TBL] [Abstract][Full Text] [Related]
6. Fine needle aspiration of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma: a case report.
Ghofrani M; Sosa JA; Ocal IT; Angeletti C
Acta Cytol; 2006; 50(5):560-2. PubMed ID: 17017447
[TBL] [Abstract][Full Text] [Related]
7. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
[TBL] [Abstract][Full Text] [Related]
9. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
[TBL] [Abstract][Full Text] [Related]
10. H3K36 trimethylation mediated by SETD2 regulates the fate of bone marrow mesenchymal stem cells.
Wang L; Niu N; Li L; Shao R; Ouyang H; Zou W
PLoS Biol; 2018 Nov; 16(11):e2006522. PubMed ID: 30422989
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
12. Roles of SETD2 in Leukemia-Transcription, DNA-Damage, and Beyond.
Skucha A; Ebner J; Grebien F
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818762
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH
J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792
[TBL] [Abstract][Full Text] [Related]
14. Hürthle cell carcinoma: current perspectives.
Ahmadi S; Stang M; Jiang XS; Sosa JA
Onco Targets Ther; 2016; 9():6873-6884. PubMed ID: 27853381
[TBL] [Abstract][Full Text] [Related]
15. SET Domain Containing 2 Deficiency in Myelodysplastic Syndrome.
Li J; Peng Z; Luo F; Chen Y
Front Genet; 2020; 11():794. PubMed ID: 32849799
[TBL] [Abstract][Full Text] [Related]
16. SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
Bu J; Chen A; Yan X; He F; Dong Y; Zhou Y; He J; Zhan D; Lin P; Hayashi Y; Sun Y; Zhang Y; Xiao Z; Grimes HL; Wang QF; Huang G
Leukemia; 2018 Apr; 32(4):890-899. PubMed ID: 29249820
[TBL] [Abstract][Full Text] [Related]
17. Histone Lysine Methyltransferase SETD2 Regulates Coronary Vascular Development in Embryonic Mouse Hearts.
Chen F; Chen J; Wang H; Tang H; Huang L; Wang S; Wang X; Fang X; Liu J; Li L; Ouyang K; Han Z
Front Cell Dev Biol; 2021; 9():651655. PubMed ID: 33898448
[TBL] [Abstract][Full Text] [Related]
18.
Tlemsani C; Luscan A; Leulliot N; Bieth E; Afenjar A; Baujat G; Doco-Fenzy M; Goldenberg A; Lacombe D; Lambert L; Odent S; Pasche J; Sigaudy S; Buffet A; Violle-Poirsier C; Briand-Suleau A; Laurendeau I; Chin M; Saugier-Veber P; Vidaud D; Cormier-Daire V; Vidaud M; Pasmant E; Burglen L
J Med Genet; 2016 Nov; 53(11):743-751. PubMed ID: 27317772
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.
Nikiforov YE
Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
Nikiforova MN; Kimura ET; Gandhi M; Biddinger PW; Knauf JA; Basolo F; Zhu Z; Giannini R; Salvatore G; Fusco A; Santoro M; Fagin JA; Nikiforov YE
J Clin Endocrinol Metab; 2003 Nov; 88(11):5399-404. PubMed ID: 14602780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
